Advances in HIV Care

Prevention of HIV Infection in Women

ASPIRE Dapivirine Ring

ASPIRE (cont) Dapivirine Ring

Ring Study Dapivirine Vaginal Ring for HIV-1 Prevention in African Women

Ring Study (cont) Dapivirine Vaginal Ring for HIV-1 Prevention in African Women

Vaginal Ring for Delivery of ART for HIV-1 Prevention in Women Is the Glass Half Full or Half Empty?

Good News, Bad News

ÉCLAIR Cabotegravir LA in HIV-Uninfected Men

ÉCLAIR (cont) Cabotegravir LA in HIV-Uninfected Men

ÉCLAIR Cabotegravir LA for Prevention of in HIV-Uninfected Men: Safety

ÉCLAIR Cabotegravir LA for Prevention of in HIV-Uninfected Men: PK

LATTE-2: Week 32 Results Cabotegravir (INSTI) + Rilpivirine (NNRTI) As LA Maintenance Therapy

LATTE-2: Week 32 Results (cont) Cabotegravir (INSTI) + Rilpivirine (NNRTI) As LA Maintenance Therapy

LATTE-2: Week 32 Results (cont) Cabotegravir (INSTI) + Rilpivirine (NNRTI) As LA Maintenance Therapy

NNRTIs

Doravirine 100mg QD vs Efavirenz + TDF/FTC In ART-Naive HIV+ Patients: Week 48 Results

Doravirine 100mg QD vs Efavirenz + TDF/FTC In ART-Naive HIV+ Patients: Week 48 Results (cont)

ACTG 5273 (SELECT) Second-Line ART Supports WHO Guidance

ACTG 5273 (SELECT) Association of NRTI Resistance at Baseline

Long-Term Adherence Challenges

A Patient Navigation/Contingency Management RCT for Hospitalized HIV+ Substance Users The Hope Study

A Patient Navigation/Contingency Management RCT for Hospitalized HIV+ Substance Users (cont) The Hope Study

Efficiency of HIV Target Cell Delivery Following Oral Administration of Tenofovir Prodrugs

Switching TDF to TAF Week 48 Results

Switching TDF to TAF (cont) Week 48 Results

Rapid Accumulation of Defective Proviruses Complicates HIV-1 Reservoir Measurements

ART Reduces Cellular HIV RNA But Not the Fraction of Proviruses Transcribing RNA

ACTG-5340 Can VRC01 Prevent or Delay the Return of Viremia After Interruption of ART?

ACTG-5326 Safety, Immunologic and Virologic Activity of Anti-PD-L1

Abbreviations

Abbreviations